Calcium Antagonists and Hormone Release. II. Effects of Verapamil on Basal, Gonadotropin-Releasing Hormoneand Thyrotropin-Releasing Hormone-Induced Pituitary Hormone Release in Normal Subjects
- 1 October 1980
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 51 (4) , 749-753
- https://doi.org/10.1210/jcem-51-4-749
Abstract
Although it has been well established that Ca2+ plays an essential role in the release of several hormones, very little is known of the interactions between Ca2+ and secretagogues in the process of pituitary hormone release. One possible way of studying the mechanism of action of hypothalamic releasing hormones is to study how organic calcium antagonist$ affect their action. Consequently, we infused the commonly used calcium antagonist, verapamil, into 20 normal subjects (10 men and 10 women; aged 19–37 yr) and studied its effects on both basal pituitary hormone levels and augmented hormonal release induced by gonadotropin-releasing hormone (GnRH) and TRH. Verapamil, infused at a rate of 5 mg/h for 3 h, induced a significant and marked suppression of circulating LH and FSH levels in both men and women. By the end of the infusion, the suppression of release was greater for LH (60%) than for FSH (54%). After the termination of the infusion, plasma gonadotropin concentrations returned progressively to basal levels within 2 h. Verapamil was also capable of blunting the peak incremental gonadotropin response to GnRH. Although the basal TSH concentration was apparently unaffected by verapamil, the incremental TSH response to TRH was significantly inhibited in both men and women. Verapamil infusion did not affect either the basal PRL concentration or the PRL response to TRH. Our data provide evidence that verapamil exerts different effects on the release of pituitary hormones in normal subjects. It inhibits the centrally mediated as well as the peripherally mediated gonadotropin release and blunts the TSH response to TRH. On the contrary, verapamil does not seem to affect basal or TRH-mediated PRL release. The use of organic calcium antagonists in experimental models in vitro as well as in vivo appears to offer a promising tool for further studies on the mechanism of action of secretagogues in the process of hormone release.Keywords
This publication has 8 references indexed in Scilit:
- KLINEFELTER'S SYNDROME: EFFECTS OF OESTROGEN ON GROWTH HORMONE, PROLACTIN AND THYROTROPHIN RELEASE, AND ON THYROTROPHIN AND PROLACTIN RESPONSES TO THYROTROPHIN-RELEASING HORMONEActa Endocrinologica, 1979
- PROLACTIN-SECRETING PITUITARY ADENOMAS: PROLACTIN DYNAMICS BEFORE AND AFTER TRANSSPHENOIDAL SURGERYActa Endocrinologica, 1979
- PRESENCE OF POSITIVE FEEDBACK BETWEEN OESTROGEN AND LH IN PATIENTS WITH KLINEFELTER'S SYNDROME, AND SERTOLI-CELL-ONLY SYNDROMEClinical Endocrinology, 1979
- The Relationship of Changes in Serum Estradiol and Progesterone during the Menstrual Cycle to the Thyrotropin and Prolactin Responses to Thyrotropin-Releasing Hormone*Journal of Clinical Endocrinology & Metabolism, 1978
- Some Effects of Energy-Transfer Inhibitors and of Ca++-Free or K+-Enhanced Media on the Release of Luteinizing Hormone (LH) from the Rat Pituitary Glandin Vitro1Endocrinology, 1968
- Presence of calcium ions as a requisite for the in vitro stimulation of TSH-release by hypothalamic TRFCellular and Molecular Life Sciences, 1967
- Potassium-induced stimulation of thyrotropin release in vitro. Requirement for presence of calcium and inhibition by thyroxineCellular and Molecular Life Sciences, 1967
- The mechanism of catecholamine release from the adrenal medulla and the role of calcium in stimulus—secretion couplingThe Journal of Physiology, 1963